ESMO 大会集中展示阿斯利康（AstraZeneca）肿瘤管线进展
STAT+: At ESMO, AstraZeneca’s cancer pursuits get a showcase
在本次 ESMO 大会上，阿斯利康（AstraZeneca）有 4 项报告入选主席研讨会环节，占该环节 12 项报告的三分之一。公司肿瘤研发负责人 Susan Galbraith 称，这体现了其产品组合的广度以及所公布数据的深度与质量。会议还展示了已获批药物新联合方案的潜力，并聚焦其下一款有望上市的靶向化疗药物。
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
MADRID — For AstraZeneca, a major oncology conference here this weekend has been a sign of how the company’s cancer work is steamrolling ahead, with highlights from a mix of old standbys and new molecules that could expand its armament of medicines even further.
Four of the 12 presentations slotted in the presidential sessions at this year’s European Society for Medical Oncology’s congress featured AZ medicines. The meeting captured just how wide-ranging the company’s cancer work is, showing the power of new combinations of approved drugs and putting a spotlight on what could be the company’s next targeted chemotherapy to reach the market.
“That does speak to the breadth of the portfolio, but also the depth and quality of the data that we’re presenting,” Susan Galbraith, the head of AZ’s cancer R&D, told STAT.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源：STAT News · statnews.com